InvestorsHub Logo
icon url

Drugdoctor

11/12/16 7:28 PM

#242 RE: dorismd2001 #241

This statement from the 8K filing describes how they are making money from these acquisitions, and will continue to add in the future.. Bolding by Drugdoctor...

In yesterday's 8K filing the Company noted that it had previously reported execution a binding term sheet on Aug. 12, 2016, whereby we agreed to acquire Pono Publications Ltd. ("Pono") and Success Nutrients, Inc. ("SNI"), both Colorado corporations, in consideration for the issuance of an aggregate of 7 million shares of our common stock. While we continue to negotiate the terms of a definitive agreement with Pono and SNI, and complete due diligence efforts, on Oct. 18, 2016, we executed an Interim Products and Services Support Agreement with both companies (the "Interim Agreement"). This Interim Agreement is intended to act as a "bridge" to allow us to work with both Pono and SNI to perpetuate our respective business plans and take advantage of our respective synergies during the time the definitive agreements are being completed. Through this agreement we will share net revenues with Pono and SNI, as applicable and expect to also benefit from the anticipated generation of new clients, and sharing of intellectual property.

In yesterday's 8K filing, the Company noted that it had previously reported signing a non-binding term sheet to acquire Capital G Ltd, an Ohio limited liability company and its three wholly owned subsidiary companies, Funk Sac LLC, Commodigy LLC, and OdorNo LLC, in consideration for the issuance of an aggregate of 1.3 million shares of our common stock. We believe that this transaction remains viable; however, the due diligence efforts are taking longer than expected. While we remain optimistic that this acquisition will be successful, the successful closing of this transaction is dependent on the outcome of our due diligence. As part of the terms included in the term sheet, we have fulfilled our agreement with Capital G Ltd. To provide funding for its operations over the past several months in the form of $250,000 in convertible debt. This note is for a one-year term and accrues interest at 12% per annum.

Andy Williams, the Company's CEO and Co-Founder added, "As we work to wrap up these synergistic acquisitions, we will continue to search for growth opportunities that will help expand our value proposition to our clients and partners and to add new lines of revenue through products and services that drive the evolution of the cannabis industry. We will continue to focus on building our brands warehouse to offer a more efficient delivery of marketing and corporate services. This November's election will mark the latest opportunity for the cannabis industry to expand into new states and create further opportunities for Medicine Man Technologies to help them do it."

The Company further announces that it has just launched a new product branded Cultivation MAX, wherein we are providing cultivation advisory services to existing operators desiring to increase their yields through deployment of our combined efficiencies. We anticipate revenues related to this new deployment to include design fees as well as income derived by formula arising from the anticipated improvement experienced in our client's cultivation practices. While no specific assurances can be provided, we believe this future income stream may be substantial based upon current performance levels noted in the cannabis cultivation landscape within states allowing for access of such related products.